Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV: A Systematic Review and Meta-analysis

Hadas Sorotsky; David Hogg; Eitan Amir; Daniel V Araujo

doi:10.1001/jamanetworkopen.2019.14816

Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV: A Systematic Review and Meta-analysis

JAMA Netw Open. 2019 Nov 1;2(11):e1914816. doi: 10.1001/jamanetworkopen.2019.14816.

Authors

Hadas Sorotsky¹, David Hogg¹, Eitan Amir¹, Daniel V Araujo¹

Affiliation

¹ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Abstract

This systematic review and meta-analysis examines factors associated with inclusion of patients with HIV in clinical trials of immune checkpoint inhibitors.

Publication types

Meta-Analysis
Systematic Review

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use
B7-H1 Antigen / analysis*
B7-H1 Antigen / antagonists & inhibitors
CTLA-4 Antigen / analysis*
CTLA-4 Antigen / antagonists & inhibitors
Cell Cycle Checkpoints / immunology*
HIV Infections / drug therapy
HIV Infections / genetics
HIV Infections / immunology*
Humans
Programmed Cell Death 1 Receptor / analysis*
Programmed Cell Death 1 Receptor / antagonists & inhibitors

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
CTLA-4 Antigen
CTLA4 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor